Excitement from the 2014 BioProcess International Award Finalists

Corporate Citizenship Finalists

“The mission of Sigma-Aldrich is to enable science to improve the quality of life, and that philosophy extends to our communities, our customers and the environment,” said Jeffrey Whitford, Manager of Global Citizenship at Sigma-Aldrich. “We are honored to be among the finalists for the BioProcess International Award for Corporate Citizenship, and we’re proud of the more than 9,000 Sigma-Aldrich employees worldwide who continue to make that mission possible each day.”

Emerging Company Finalists

“ToleRaM Nanotech is delighted with being recognized as a finalist for the BioProcess International 2014 “Emerging Company” award. We are dedicated to the efficient delivery of targeted nanotherapeutics by merging bioengineering with medicine, and are truly honored by this recognition,” said Satish N. Nadig, M.D., Ph.D. Title: Chief Medical Officer (CMO) ToleRaM Nanotech; Assistant Professor of Surgery, Microbiology & Immunology – Medical University of South Carolina

“With a rigorous selection process and an impressive peer group, BioCision views being a BioProcess International finalist an important company milestone,” said Dr. Rolf Ehrhardt, CEO, BioCision. “This award not only recognizes BioCision for our innovation but also raises awareness of the need to protect the integrity of temperature-sensitive biospecimens and therapeutics.”

Excellence in Leadership Finalists

“Receiving this award means a lot to me as an individual but more importantly the recognition means a lot to our entire team. Three years ago we decided to work together to bring an innovative full solutions approach to biotherapeutic manufacturing that would address the changing needs that we were seeing in the market place. It was an educated bet but it was definitely the right decision and receiving such positive feedback from our industry peers is very humbling, and I would like to thank everyone involved. We are really excited about what we are achieving together and we feel that the best is still to come,” said Olivier Loeillot, GM Enterprise Solutions and Commercial BioProcess, Asia, GE Healthcare Life Sciences

“Being recognized for the BioProcess International 2014 Excellence in Leadership Award was a complete surprise. It is an honor to be thought of so prestigiously by my colleagues, and yet incredibly humbling as it has been such a short time that I’ve served as their leader. Making an impact on colleagues every day is the most rewarding role I could ever ask for,” said Lynn Bottone, Site Leader, Sanford Site, Pfizer

“I am truly honored to have been selected as a finalist of the BioProcess International 2014 Excellence in Leadership Award. At PCT, we pride ourselves on helping our clients to be forward thinking – looking ahead with an eye towards the commercialization of cell therapies with a focus on reliability and product quality. I would also like to thank BioProcess International for holding this award series to acknowledge all of the hard work that occurs at by individuals and companies, and across many areas including corporate citizenship and facility design. This award series helps remind us all that we are working towards, to quote BPI, “allowing the industry to deliver better, more effective treatments to a global patient base,” said Dr. Robert Preti, Visionary Founder, President and Chief Scientific Officer Progenitor Cell Therapy (PCT).

Excellence in Facility Design/Retrofit Finalists

“We are honored to be named one of the three finalists of this year’s BioProcess International 2014 Awards in the category of ‘Excellence in Facility Design and Retrofit’. The award demonstrates the relevance of continuous investment in technology and process optimization to meet the increasing requirements of today’s pharmaceutical industry,” said Thomas Otto, Managing Director, Vetter

Best Collaboration Finalists

“It is a fantastic honor to be nominated for the BioProcess International 2014 Award, along with TAP Biosystems, for both Best Collaboration and Best Technology Application-Upstream for the development of the Ambr250 automated bioreactor system. The collaboration and resulting Ambr250 technology was intended to have true value to end users through the improvement of productivity, accuracy, consistency, and the work life balance of the scientist. Being nominated as a finalist in these categories shows the value the technology brings to these areas,” said Christopher Kistler, Principal Scientist, Merck & Co., Inc.

“We spend a lot of time trying to understand the requirements of the end-users and the context into which our systems are placed. Being a BioProcess International 2014 Awards finalist with the excellent team from Merck is an acknowledgement that such time and effort is really worthwhile,” said Richard Wales, Director Business Development, TAP Biosystems, Part of the Sartorius Stedim Biotech Group

Analytical Best Technology Application Finalists

“Amnis, part of EMD Millipore is honored to be recognized with our collaborator, Enzo Life Sciences, as finalists for a BioProcess International 2014 Award for our work on the enumeration and characterization of protein aggregates and contaminants in biopharmaceutical formulations. We believe that our powerful imaging flow cytometry products, coupled with Enzo’s novel ProteoStat® reagent, will allow the biopharmaceutical industry to greatly improve product quality and conform to FDA guidelines and regulations,” said David Basiji, Ph.D. , Co-founder, Amnis – Part of EMD Millipore

Upstream Best Technology Applications Finalists

“It is a fantastic honor to be nominated for the BioProcess International 2014 Award, along with TAP Biosystems, for both Best Collaboration and Best Technology Application-Upstream for the development of the Ambr250 automated bioreactor system. The collaboration and resulting Ambr250 technology was intended to have true value to end users through the improvement of productivity, accuracy, consistency, and the work life balance of the scientist. Being nominated as a finalist in these categories shows the value the technology brings to these areas,” said Christopher Kistler, Principal Scientist, Merck & Co., Inc.

“We spend a lot of time trying to understand the requirements of the end-users and the context into which our systems are placed. Being a BioProcess International 2014 Awards finalist with the excellent team from Merck is an acknowledgement that such time and effort is really worthwhile,” said Richard Wales, Director Business Development, TAP Biosystems, Part of the Sartorius Stedim Biotech Group

Downstream Technology Application Finalists

“With a rigorous selection process and an impressive peer group, BioCision views being a BioProcess International finalist an important company milestone,” said Dr. Rolf Ehrhardt, CEO, BioCision. “This award not only recognizes BioCision for our innovation but also raises awareness of the need to protect the integrity of temperature-sensitive biospecimens and therapeutics.”

BioProcess International Awards 2014 Ceremony Highlights:

Leave a Reply